Nektar completes enrollment in BEACON trial of NKTR-102 in patients with metastatic b
Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.